Amphotericin B lipid complex at 3 mg/kg/day for treatment of invasive fungal infections in adults with haematological malignancies

Journal of Antimicrobial Chemotherapy

Volumn 44, Issue 4, 1999, Pages 569-572

  Martino, Rodrigo ^a   Subirá, Maricel ^a   Sureda, Anna ^a   Sierra, Jorge ^a  

^a HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; ANTIFUNGAL AGENT;

ADULT; ARTICLE; ASPERGILLOSIS; CANDIDIASIS; CLINICAL ARTICLE; CLINICAL TRIAL; CREATININE BLOOD LEVEL; DRUG EFFICACY; FEMALE; HUMAN; KIDNEY FUNCTION; LEUKEMIA; MALE; MYCOSIS;

ADULT; AMPHOTERICIN B; ANTIFUNGAL AGENTS; DRUG COMBINATIONS; FEMALE; HUMANS; LEUKEMIA; MALE; MIDDLE AGED; MYCOSES; PHOSPHATIDYLCHOLINES; PHOSPHATIDYLGLYCEROLS;

EID: 0032858775     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/44.4.569     Document Type: Article

References (10)

1. Khoo, S. H., Bond, J. & Denning, D. W. (1994). Administering amphotericin B - A practical approach. Journal of Antimicrobial Chemotherapy 33, 201-13.
2. Denning, D. W. (1998). Invasive aspergillosis. Clinical Infectious Diseases 26, 781-805.
3. Walsh, T. J., Hiemenz, J. W., Seibel, N. L., Perfect, J. R., Horwith, G., Lee, L. et al. (1998). Amphotericin B lipid complex for invasive fungal infections: analysis of safety and efficacy in 556 cases. Clinical Infectious Diseases 26, 1383-96.
4. Clevenbergh, P., Jacobs, P., Kentos, A., Byl, B., Collignon, L., Moerman, M. et al. (1998). Compassionate use of amphotericin B lipid complex (Abelcet) in life-threatening fungal infections: report of 30 cases. Clinical Microbiology and Infection 4, 192-8.
5. Hiemenz, J. W. & Walsh, T. J. (1996). Lipid formulations of amphotericin B: recent progress and future directions. Clinical Infectious Diseases 22, Suppl. 2, S133-44.
6. Adedoyin, A., Bernardo, J. F., Swenson, C. E., Bolsack, L. E., Horwith, G., DeWit, S. et al. (1997). Pharmacokinetic profile of ABELCET (Amphotericin B lipid complex injection): combined experience from phase I and phase II studies. Antimicrobial Agents and Chemotherapy 41, 2201-8.
7. Linden, P. (1997). Efficacy of low-dose ABELCET (Amphotericin B lipid complex). In Abstracts of Focus on Fungal Infections 7, San Antonio, Texas, 1997. Abstract 268, p. 59.
8. Sharkey, P. K., Graybill, J. R., Johnson, E. S., Hausrath, S. G., Pollard, R. B., Kolokathis, A. et al. (1996). Amphotericin B lipid complex compared with amphotericin B in the treatment of cryptococcal meningitis in patients with AIDS. Clinical Infectious Diseases 22, 315-21.
9. Walsh, T. J., Whitcomb, P., Piscitelli, S., Figg, W. D., Hill, S., Chanock, S. J. et al. (1997). Safety, tolerance, and pharmacokinetics of amphotericin B lipid complex in children with hepatosplenic candidiasis. Antimicrobial Agents and Chemotherapy 41, 1944-8.
10. Sundar, S., Agrawal, N. K., Sinha, P. R., Horwith, G. S. & Murray, H. W. (1997). Short-course, low-dose amphotericin B lipid complex therapy for visceral leishmaniasis unresponsive to antimony. Annals of Internal Medicine 127, 133-7.